NCT02884635

A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate

Phase IIa Study of ASP1707 A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Phase 2a Study of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy, pharmacokinetics, pharmacodynamics and safety of ASP1707 in combination with MTX in postmenopausal female patients with RA.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	ASP1707	Oral
DRUG	Placebo	Oral
DRUG	Methotrexate	Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.

Timeline

• Start date: 2016-09-16
• Primary completion: 2017-10-18
• Completion: 2017-10-25
• First posted: 2016-08-31
• Last updated: 2024-10-23

Locations

27 sites across 1 country: Japan